GlassScriptPhysician profile
Marquetta D Colbert
NPI 1891932208
$11,298.08
in general payments reported to CMS, 2019-2025
46 companies · $2,681 in 2025
The $2,681 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,229 · 2022: $2,093 · 2023: $2,400 · 2024: $1,896 · 2025: $2,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,976.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,330.70 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $1,204.57 | 2021-2025 | Biktarvy |
| Abbvie INC. | $1,046.95 | 2021-2025 | |
| Lilly USA, LLC | $628.47 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $576.24 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $564.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $518.00 | 2022-2025 | |
| Pfizer INC. | $496.26 | 2021-2025 | |
| Dexcom, INC. | $476.07 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.52 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $415.55 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $302.42 | 2021-2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $282.30 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.09 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $231.86 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $200.75 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $178.43 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $163.18 | 2022-2024 | Quviviq |
| Mannkind Corporation | $159.35 | 2021-2023 | Afrezza |
| Viiv Healthcare Company | $138.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $138.25 | 2021-2023 | Steglatro, Belsomra, Verquvo |
| Alkermes, INC. | $138.12 | 2023-2025 | Vivitrol, Vivitrol |
| Xeris Pharmaceuticals, INC. | $129.79 | 2022-2025 | Gvoke Hypopen |
| Zealand Pharma US, INC. | $114.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $105.23 | 2022-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $103.80 | 2024-2025 | Qelbree |
| Lundbeck LLC | $99.19 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $90.67 | 2021-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $83.66 | 2021-2022 | |
| Cequr Corporation | $77.96 | 2024-2025 | Cequr Simplicity |
| Amarin Pharma, INC. | $72.11 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.50 | 2021 | |
| Amgen INC. | $60.32 | 2021-2025 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $53.26 | 2025 | Symbravo |
| Tempus Ai, INC | $50.44 | 2024 | |
| Evoke Pharma, INC. | $47.51 | 2023 | Gimoti |
| Biohaven Pharmaceutical Holding Company LTD. | $42.39 | 2022 | |
| Exact Sciences Corporation | $38.99 | 2025 | The Cologuard Plus Collection Kit |
| Exeltis, USA INC. | $35.50 | 2025 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $30.72 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.47 | 2021-2022 | |
| Corcept Therapeutics | $17.99 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $16.10 | 2025 | Cobenfy |
| Mycovia Pharmaceuticals, INC. | $16.01 | 2023 | Vivjoa |
| Scynexis, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marquetta Colbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.